Medication info
Empagliflozin and Metformin Extended-Release Tablets 5/1000 mg (Empagliflozin, Metformin)

Empagliflozin and Metformin Extended-Release Tablets 5/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Pale pink oval-shaped extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501902 · Approved 2025.07.24 · Insurance code 643508980

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride 2000 mg as extended-release formulation. To reduce gastrointestinal adverse reactions caused by metformin, take this medication once daily in the evening with a meal. Take 1 tablet of this medication as 10/1000 mg extended-release tablets or 25/1000 mg extended-release tablets once daily. Patients taking this medication as 5/1000 mg extended-release tablets or 12.5/1000 mg extended-release tablets should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medications such as insulin, the recommended initial total daily dose when taking this medication is empagliflozin 10 mg and the patient’s current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from concomitant therapy with empagliflozin and metformin to this medication should receive their existing doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. ⦁ When this medication is co-administered with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dose adjustment based on renal function may be necessary, renal function should be assessed before starting this medication and periodically during treatment. No dose adjustment of this medication is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medication may be used by adjusting the dose of metformin hydrochloride as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medication. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this medication should be discontinued immediately. In patients aged 75 years and older, renal function and the risk of volume depletion should be taken into consideration.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

View approved original text

This medication is used to improve blood sugar control in patients with type 2 diabetes by combining empagliflozin and metformin. It is effective for adult patients whose blood sugar is not sufficiently controlled, when administered alongside dietary changes and exercise therapy. It is particularly used in patients with type 2 diabetes who have cardiovascular disease, and reference should be made to expert guidelines regarding related cardiovascular events. This medication is actively used to aid in the management of diabetes and improve blood sugar control.

How to take

Adult dose

The dose of this medication for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride 2000 mg as extended-release formulation. To reduce gastrointestinal adverse reactions caused by metformin, take this medication once daily in the evening with a meal. Take 1 tablet of this medication as 10/1000 mg extended-release tablets or 25/1000 mg extended-release tablets once daily. Patients taking this medication as 5/1000 mg extended-release tablets or 12.5/1000 mg extended-release tablets should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medications such as insulin, the recommended initial total daily dose when taking this medication is empagliflozin 10 mg and the patient’s current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from concomitant therapy with empagliflozin and metformin to this medication should receive their existing doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. ⦁ When this medication is co-administered with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dose adjustment based on renal function may be necessary, renal function should be assessed before starting this medication and periodically during treatment. No dose adjustment of this medication is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medication may be used by adjusting the dose of metformin hydrochloride as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medication. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this medication should be discontinued immediately. In patients aged 75 years and older, renal function and the risk of volume depletion should be taken into consideration.

Precautions

This medication is used in the treatment of diabetes and works with two components to control blood sugar. Rare but serious side effects such as lactic acidosis may occur while taking this medication, so caution is advised, especially in patients with impaired renal function or cardiovascular disease. Additionally, taking this medication with insulin or sulfonylureas may increase the risk of hypoglycemia, so blood sugar levels must be monitored closely. Patients with moderate to severe renal impairment, acute renal problems, severe infections, heart failure, or acute myocardial infarction should not use this medication. Before and after tests using iodinated contrast agents, the intake of this medication should be temporarily suspended due to the risk of renal function deterioration and lactic acidosis, resuming only after renal function is confirmed to be normal. It is also advised that women who are pregnant or may become pregnant, patients with severely impaired liver function, and those in significantly poor nutritional status should avoid using this medication. While taking this medication, side effects such as hypoglycemia, urinary tract infections, genital infections, increased urination, gastrointestinal disorders (nausea, vomiting, diarrhea, etc.), hepatic dysfunction, skin rash, and others may occur, and any abnormal symptoms should be discussed with a healthcare provider. Particularly, elderly patients or those at risk of fluid loss should pay attention to dehydration or hypotension and must have their renal function regularly examined. Taking this medication along with alcohol increases the risk of lactic acidosis, so alcohol consumption should be avoided. The tablets should be swallowed whole and not chewed or crushed; the tablet coating may appear in stool but this is normal. It is important to regularly check blood sugar control and to consult a healthcare provider regarding potential drug interactions when combining this medication with others. In case of overdose, immediate hospital care should be sought, and rapid medical intervention is necessary if lactic acidosis is suspected.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
Show 151 more
  • constipation
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • itching
  • rash
  • hives
  • erythema
  • angioedema
  • difficulty urinating
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • decreased and deficiency of vitamin B12
  • ketoacidosis
  • perineal necrosis
  • chronic gastritis
  • various neurological disorders
  • cerebral infarction
  • soft tissue inflammation
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • ischemic colitis
  • intestinal bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • fallopian tube-ovarian abscess
  • vestibular neuritis
  • headache
  • orthostatic dizziness
  • dizziness
  • weakness
  • chest discomfort
  • chest pain
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • urinary stones
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • urination pain
  • abnormal urine
  • vulvar pruritus
  • benign prostatic hyperplasia
  • cervical inflammation
  • hyperglycemia
  • hyponatremia
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • circular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • macular fibrosis
  • ocular discomfort
  • eye congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • traction retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • nosebleed
  • asthma
  • exertional dyspnea
  • moist cough
  • allergic rhinitis
  • residual phlegm
  • cough
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • falls
  • hand fracture
  • iliotibial band syndrome
  • open eye injury
  • pelvic fracture
  • road traffic accident
  • spleen injury
  • sternal fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular disorder
  • peripheral arterial occlusive disease
  • anxiety
  • depression
  • sleep disorder
  • acute cholecystitis
  • autoimmune hepatitis
  • gallstones
  • hepatitis
  • otalgia
  • orthostatic dizziness
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid mass
  • constipation
  • dyspepsia
  • abdominal pain
  • gastritis
  • gastrointestinal disorder
  • shingles
  • drowsiness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture and kept at room temperature between 1 and 30 degrees Celsius. Proper storage can maintain the effectiveness of the medication and prevent deterioration.

Appearance and packaging

Appearance

Pale pink oval-shaped extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.